Mainstream

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

Post ContentroivRead More

You might also be interested in reading Flow (FLOW), Aave (AAVE), And BudBlockz (BLUNT) are on Track For a Remarkable Rise In 2023.

February 10, 2025
In Mainstream